Stella Pharma Corp. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Cyfuse Biomedical KK

Peptidream, Inc.

SUSMED, Inc.

Chiome Bioscience, Inc.

StemCell Institute

OncoTherapy Science, Inc.

GNI Group Ltd.

Oncolys BioPharma, Inc.

Carna Biosciences, Inc.

MEDINET Co., Ltd.

Stella Pharma Corp.

Why is Stella Pharma Corp. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Poor long term growth as Operating profit has grown by an annual rate -234.76% of over the last 5 years

NET SALES(Q) Lowest at JPY 61.6 MM
INTEREST(Q) Highest at JPY 1.47 MM
OPERATING PROFIT(Q) Lowest at JPY -206.55 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 113.75%, its profits have risen by 81.6%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Stella Pharma Corp. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Stella Pharma Corp.

113.75%

1.60

85.08%

Japan Nikkei 225

36.73%

1.30

28.24%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

65.01%

EBIT Growth (5y)

-234.76%

EBIT to Interest (avg)

-188.60

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.76

Sales to Capital Employed (avg)

0.13

Tax Ratio

2.13%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.85

EV to EBIT

-109.86

EV to EBITDA

-178.57

EV to Capital Employed

12.91

EV to Sales

10.32

PEG Ratio

Dividend Yield

ROCE (Latest)

-11.75%

ROE (Latest)

-4.39%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 0.54% (YoY

-32What is not working for the Company

NET SALES(Q)

Lowest at JPY 61.6 MM

INTEREST(Q)

Highest at JPY 1.47 MM

OPERATING PROFIT(Q)

Lowest at JPY -206.55 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -335.32 %

PRE-TAX PROFIT(Q)

Lowest at JPY -203.52 MM

NET PROFIT(Q)

Lowest at JPY -204.23 MM

EPS(Q)

Lowest at JPY -6

Here's what is working for Stella Pharma Corp.

Raw Material Cost

Fallen by 0.54% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Stella Pharma Corp.

Net Sales

At JPY 61.6 MM has Fallen at -75.16%

over average net sales of the previous four periods of JPY 247.96 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (JPY MM)

Pre-Tax Profit

At JPY -203.52 MM has Fallen at -359.79%

over average net sales of the previous four periods of JPY -44.26 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Net Profit

At JPY -204.23 MM has Fallen at -353.82%

over average net sales of the previous four periods of JPY -45 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (JPY MM)

Net Sales

Lowest at JPY 61.6 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (JPY MM)

Interest

Highest at JPY 1.47 MM

in the last five periods and Increased by 8.9% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Operating Profit

Lowest at JPY -206.55 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (JPY MM)

Operating Profit Margin

Lowest at -335.32 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at JPY -203.52 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (JPY MM)

Net Profit

Lowest at JPY -204.23 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (JPY MM)

EPS

Lowest at JPY -6

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (JPY)